Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $1.3 billion.

  • Northwest Biotherapeutics' Shares Outstanding (Weighted Average) rose 18.76% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 18.76%. This contributed to the annual value of $1.3 billion for FY2024, which is 12.45% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $1.3 billion for FY2024, which was up 12.45% from $1.2 billion recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) peaked at $1.3 billion during FY2024, and registered a low of $731.5 million during FY2020.
  • Over the past 3 years, Northwest Biotherapeutics' median Shares Outstanding (Weighted Average) value was $1.2 billion (recorded in 2023), while the average stood at $1.2 billion.
  • Data for Northwest Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 26.83% (in 2021) over the last 5 years.
  • Northwest Biotherapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $731.5 million in 2020, then grew by 26.83% to $927.8 million in 2021, then increased by 13.48% to $1.1 billion in 2022, then rose by 9.59% to $1.2 billion in 2023, then rose by 12.45% to $1.3 billion in 2024.